Response of retinal vessels to anti vascular endothelial growth factor (VEGF) treatment in patients with branch retinal vein occlusion (BRVO)

Medical University of Vienna0 个研究点开始时间: 2007年8月29日最近更新: 2013年4月8日

试验速览

暂无简介。

•-male or female, at least 18 years of age.
•-ophthalmoscopic evidence of recent BRVO, that is, a history of 3 months.
•-macular edema secondary to BRVO in the study eye scheduled for intravittreal anti-VEGF as primary treatment.
•-retinal thickness of > 300 µm by OCT in the central subfield of the study eye at baseline.
•-VA decrease attributable to the edema.
•-written informed consent has been obtained.
•-female patients of childbearing potential must have a negative urine pregnancy test.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Uncontrolled sytemic disease
•-Symptoms of a clinically relevant illness in the 3 weeks before the first study day
•-Any ocular condition that in the opinion of the investigator would prevent a 15-letter improvement in visual acuity (eg severe macular ischemia)
•- History of glaucoma, aphakie or presence of anterior chamber intraocular lens, active reinal neovascularisation, choroidal neovascularisation, significant cataract, presence of rubeosis iridis, any ocular infection, history of pars plana vitrectomy, anticipated need for ocular surgery in the study eye during the study perios.
•-contraindication to pupil dilation known allergy or contraindication to the use of fluorescein.
•- Pregnancy

发起方